샘플 요청 목록

 카트 문의
시장보고서
상품코드
1866606

세계의 듀센형 근이영양증(DMD) 치료제 시장 : 시장 점유율과 순위, 전체 판매 및 수요 예측(2025-2031년)

Duchenne Muscular Dystrophy (DMD) Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
발행일: | 리서치사: QYResearch | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

세계의 듀센형 근이영양증(DMD) 치료제 시장 규모는 2024년에 21억 7,000만 달러로 추정되며, 2025년부터 2031년까지 예측 기간 동안 CAGR 13.1%로 확대되어 2031년까지 47억 7,600만 달러로 재조정될 전망입니다.

듀센형 근이영양증(DMD 또는 단순히 듀쉔이라고도 함)은 드문 유전성 질환입니다. 주로 남성에게 영향을 미치지만, 드물게 여성에게도 발병할 수 있습니다. 듀센형 근이영양증은 시간이 지남에 따라 체내 근육이 약화되고 손상되어 결국 치명적인 결과를 초래합니다. 듀센형 근이영양증을 유발하는 유전적 변화(DMD 유전자 돌연변이)는 출생 전에 발생하여 유전되는 경우도 있고, 유전자에 새로운 돌연변이가 자연적으로 발생하는 경우도 있습니다. 근력저하는 3세에서 5세 사이에 두드러지게 나타나기 시작하며, 대부분의 환자들은 12세까지 휠체어를 사용하게 됩니다. 사춘기에는 심장과 호흡근육이 약해져 심각한 생명을 위협하는 합병증을 유발합니다.

듀센형 근이영양증(DMD) 치료 시장은 주로 다음과 같은 요인에 의해 주도되고 있습니다:

I. 질병 부담과 미충족 수요

높은 장애율과 사망률:

DMD는 진행성 근위축성 질환입니다. 환자는 보통 10세 전후에 보행 능력을 상실하고, 20-30세 사이에 심폐 기능 부전으로 사망합니다. 전 세계적으로 약 30만 건, 중국에서는 7만 건 이상이 보고되어 사회적으로 큰 부담으로 작용하고 있습니다.

여성 보균자가 남자아이를 출산하면 그 아이가 질병을 물려받을 확률은 50%로 가족 내 유전 위험이 매우 높습니다.

기존 치료법의 한계:

현재 주류 치료인 코르티코스테로이드(데플라자코트 등)나 국소 엑손 스키핑제(엑손디에스51 등)는 질병의 진행을 늦출 수는 있지만 근본적인 치료는 불가능하며, 장기적인 사용이 필요하고 심각한 부작용을 수반합니다.

특정 유전자 변이 유형(엑손 51/53 스킵 등)에만 적용되기 때문에 적용 대상 환자군이 한정되어 있어 보편적인 치료법이 부족한 실정입니다.

진단율 향상:

의료 인프라가 정비되고 도시화가 진행됨에 따라 중국의 DMD 진단율은 2022년 약 30%에서 2025년 50% 이상으로 상승할 것으로 예상되며, 더 많은 환자들이 치료를 필요로 하는 계층에 합류할 것으로 예상됩니다.

II. 연구 개발의 진전 및 파이프라인의 획기적인 발전

유전자 치료 및 올리고뉴클레오티드 기술의 획기적인 발전:

유전자 치료 분야에서는 살렙타의 SRP-9001(AAVrh74 벡터를 이용한 마이크로디스트로핀 도입), 페이스 파마슈티컬스의 BBM-D101(변형 AAV 벡터) 등 단회 투여로 장기적인 단백질 발현을 실현하는 치료법이 개발되고 있습니다. 임상시험에서 양성 근섬유의 비율이 크게 증가하는 것이 확인되었습니다.

Huida Gene의 CRISPR-Cas12 유전자 편집 치료는 유전자 돌연변이 복구를 목표로 임상시험 단계에 진입했습니다.

펩젠의 PGN-EDO51, 엔트라다의 ENTR-601-44 등 안티센스 올리고뉴클레오티드(ASO) 및 차세대 펩타이드 결합 올리고뉴클레오티드(PPMO)를 포함한 올리고뉴클레오티드 요법은 세포 내 흡수 및 리소좀 탈출을 강화하여 효능을 향상시키고 투여량을 줄입니다.

국내의 활발한 연구개발 파이프라인:

중국에서는 10가지 이상의 DMD 치료제가 임상시험 단계에 있으며, 유전자 편집(예 : 혜달 유전자의 CRISPR-Cas12), AAV 유전자 치료(금위생물체의 JWK007), 미니 단백질 의약품(신앙의약의 BBM-D101) 등이 포함됩니다. 일부는 FDA 희귀의약품으로 지정되어 2026년 이후 출시가 기대되고 있습니다.

III. 정책적 지원 및 결제 환경의 최적화

희귀질환에 대한 정책적 지원:

미국 : DUX법에 따라 DMD 희귀질환 치료제의 시장 독점 기간이 7.5년으로 연장되었고, 신속 승인 절차를 통해 시판 기간이 34% 단축되었습니다.

중국 : 2024년 시행 예정인 제2차 희귀질환 리스트에 DMD가 추가되어 국내 연구개발이 촉진됩니다. 의료보험 적용 범위가 확대되고, 바몰롤론은 전국 의료보험 협상 대상에 선정되었습니다. 국산 유전자 치료제의 가격은 2026년까지 200만 위안 이하로 떨어질 것으로 예상됩니다.

비용 효율성 향상:

북미 : 유나이티드헬스케어 등 민간 보험사가 DMD 유전자 치료에 대한 보험 적용을 우선적으로 시행하고 있으며, 의료보험 적용률은 80%를 상회하고 있습니다. 유럽에서는 HTA 평가를 통과한 제품의 상환율이 80%를 넘지만, 제품 출시는 미국보다 9-15개월 정도 늦어지고 있습니다.

아시아태평양 : 중국, 일본, 한국 등의 시장은 괄목할만한 성장세를 보이고 있으며, 정책과 자본이 결합하여 치료 접근성을 촉진하고 있습니다.

DMD 치료 시장은 질병의 심각성, 기술적 혁신, 유리한 정책에 의해 주도되고 있습니다. 유전자 편집 요법과 RNA 요법이 미래를 주도할 것으로 예상되지만, 높은 비용과 생산능력의 병목현상(AAV 벡터 생산 등)은 여전히 극복해야 할 과제입니다. 기업은 미충족 수요에 대응하기 위해 기술 혁신과 결제 모델 최적화에 집중해야 합니다.

이 보고서는 세계 듀센형 근이영양증(DMD) 치료제 시장에 대해 총 매출액, 주요 기업의 시장 점유율 및 순위를 중심으로 지역별, 국가별, 유형별, 용도별 분석을 종합적으로 제시하는 것을 목적으로 합니다.

듀센형 근이영양증(DMD) 치료제 시장의 규모, 추정 및 예측은 매출액 기준으로 제시되며, 2024년을 기준 연도로 하여 2020년부터 2031년까지의 과거 데이터와 예측 데이터를 포함하고 있습니다. 정량적, 정성적 분석을 통해 독자들이 듀센형 근이영양증(DMD) 치료제 관련 사업/성장 전략 수립, 시장 경쟁 평가, 현재 시장에서의 포지셔닝 분석, 정보에 입각한 사업적 판단을 내릴 수 있도록 돕습니다.

시장 세분화

기업별

  • Sarepta Therapeutics
  • PTC Therapeutics
  • Pfizer
  • Bristol-Myers Squibb
  • Italfarmaco
  • Santhera Pharmaceuticals

유형별 부문

  • 엑손디스
  • 엠플라자
  • 트랜스라나

용도별 부문

  • 병원
  • 진료소
  • 재택의료

지역별

  • 북미
    • 미국
    • 캐나다
  • 아시아태평양
    • 중국
    • 일본
    • 한국
    • 동남아시아
    • 인도
    • 호주
    • 기타 아시아태평양
  • 유럽
    • 독일
    • 프랑스
    • 영국
    • 이탈리아
    • 네덜란드
    • 북유럽 국가
    • 기타 유럽
  • 라틴아메리카
    • 멕시코
    • 브라질
    • 기타 라틴아메리카
  • 중동 및 아프리카
    • 튀르키예
    • 사우디아라비아
    • 아랍에미리트
    • 기타 중동 및 아프리카
KSM 25.11.26

The global market for Duchenne Muscular Dystrophy (DMD) Therapeutics was estimated to be worth US$ 2170 million in 2024 and is forecast to a readjusted size of US$ 4776 million by 2031 with a CAGR of 13.1% during the forecast period 2025-2031.

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne-a mutation in the DMD gene-happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.

The Duchenne muscular dystrophy (DMD) treatment market is primarily driven by the following factors:

I. Disease Burden and Unmet Needs

High Disability and Mortality Rates:

DMD is a progressive muscle wasting disease. Patients typically lose the ability to walk around age 10 and die from cardiopulmonary failure between the ages of 20 and 30. With approximately 300,000 cases worldwide and over 70,000 in China, the disease poses a significant social burden.

If a female carrier gives birth to a boy, there is a 50% chance that the child will inherit the disease, creating a high family genetic risk.

Limitations of Existing Treatments:

Current mainstream treatments, including corticosteroids (such as deflazacort) and topical exon-skipping drugs (such as Exondys 51), can only delay the disease, not cure it, and require long-term use with significant side effects.

There is a lack of universal treatments, which only cover specific gene mutation types (such as exon 51/53 skipping), limiting their applicable population.

Improved Diagnosis Rate:

With improved medical infrastructure and urbanization, China's DMD diagnosis rate is expected to rise from approximately 30% in 2022 to over 50% in 2025, bringing more patients into the treatment-needing population.

II. R&D Progress and Pipeline Breakthroughs

Breakthroughs in Gene Therapy and Oligonucleotide Technologies:

Gene therapies, such as Sarepta's SRP-9001 (microdystrophin delivered via an AAVrh74 vector) and Faith Pharmaceuticals' BBM-D101 (engineered AAV vector), achieve long-term protein expression with a single dose. Clinical trials have shown a significant increase in the percentage of positive fibers.

Huida Gene's CRISPR-Cas12 gene editing therapy has entered clinical trials, targeting gene mutation repair.

Oligonucleotide therapies, including antisense oligonucleotides (ASOs) and next-generation peptide-coupled oligonucleotides (PPMOs), such as PepGen's PGN-EDO51 and Entrada's ENTR-601-44, enhance cellular uptake and lysosomal escape, improving efficacy and reducing dosage.

Active Domestic R&D Pipeline:

Over 10 DMD drugs have entered clinical trials in China, including gene editing (such as Huida Gene's CRISPR-Cas12), AAV gene therapy (Jinwei Bio's JWK007), and mini-protein drugs (Faith Pharmaceuticals' BBM-D101). Some have received FDA orphan drug designation and are expected to be launched after 2026.

III. Policy Support and Optimized Payment Environment

Policy Support for Rare Diseases:

US: The DUX Act extends the market exclusivity period for DMD orphan drugs to 7.5 years, and the accelerated approval process shortens drug launch time by 34%.

China: DMD will be included in the second round of rare disease listings in 2024, promoting domestic R&D. Medical insurance coverage has expanded, with vamorolone included in the national medical insurance negotiations. The price of domestically produced gene therapies is expected to drop below 2 million yuan by 2026.

Improved Affordability:

North America: Commercial insurance companies (such as UnitedHealthcare) have prioritized DMD gene therapy reimbursement, with medical insurance coverage exceeding 80%. In Europe, reimbursement rates for products that pass HTA assessment exceed 80%, but product launches lag 9-15 months behind those in the US.

Asia-Pacific: Markets such as China, Japan, and South Korea are experiencing significant growth, with policies and capital jointly driving therapeutic accessibility.

The DMD therapy market is driven by disease severity, technological breakthroughs, and favorable policies. Gene editing and RNA therapies will dominate the future, but high costs and production capacity bottlenecks (such as AAV vector production) still need to be overcome. Companies need to focus on technological innovation and payment model optimization to address unmet medical needs.

This report aims to provide a comprehensive presentation of the global market for Duchenne Muscular Dystrophy (DMD) Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Duchenne Muscular Dystrophy (DMD) Therapeutics by region & country, by Type, and by Application.

The Duchenne Muscular Dystrophy (DMD) Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Duchenne Muscular Dystrophy (DMD) Therapeutics.

Market Segmentation

By Company

  • Sarepta Therapeutics
  • PTC Therapeutics
  • Pfizer
  • Bristol-Myers Squibb
  • Italfarmaco
  • Santhera Pharmaceuticals

Segment by Type

  • Exondys
  • Emflaza
  • Translarna

Segment by Application

  • Hospitals
  • Clinics
  • Home Care

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Duchenne Muscular Dystrophy (DMD) Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Duchenne Muscular Dystrophy (DMD) Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Duchenne Muscular Dystrophy (DMD) Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Product Introduction
  • 1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Forecast (2020-2031)
  • 1.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trends & Drivers
    • 1.3.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Trends
    • 1.3.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers & Opportunity
    • 1.3.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Challenges
    • 1.3.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Players Revenue Ranking (2024)
  • 2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Company (2020-2025)
  • 2.3 Key Companies Duchenne Muscular Dystrophy (DMD) Therapeutics Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Duchenne Muscular Dystrophy (DMD) Therapeutics
  • 2.6 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Competitive Analysis
    • 2.6.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Exondys
    • 3.1.2 Emflaza
    • 3.1.3 Translarna
  • 3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type
    • 3.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, by Type (2020-2031)
    • 3.2.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Hospitals
    • 4.1.2 Clinics
    • 4.1.3 Home Care
  • 4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application
    • 4.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, by Application (2020-2031)
    • 4.2.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region
    • 5.1.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region (2020-2025)
    • 5.1.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region (2026-2031)
    • 5.1.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
    • 5.2.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
    • 5.3.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
    • 5.5.2 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
    • 6.3.2 United States Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
    • 6.4.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
    • 6.5.2 China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
    • 6.6.2 Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
    • 6.7.2 South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
    • 6.9.2 India Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Sarepta Therapeutics
    • 7.1.1 Sarepta Therapeutics Profile
    • 7.1.2 Sarepta Therapeutics Main Business
    • 7.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
    • 7.1.4 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Sarepta Therapeutics Recent Developments
  • 7.2 PTC Therapeutics
    • 7.2.1 PTC Therapeutics Profile
    • 7.2.2 PTC Therapeutics Main Business
    • 7.2.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
    • 7.2.4 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.2.5 PTC Therapeutics Recent Developments
  • 7.3 Pfizer
    • 7.3.1 Pfizer Profile
    • 7.3.2 Pfizer Main Business
    • 7.3.3 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
    • 7.3.4 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Pfizer Recent Developments
  • 7.4 Bristol-Myers Squibb
    • 7.4.1 Bristol-Myers Squibb Profile
    • 7.4.2 Bristol-Myers Squibb Main Business
    • 7.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
    • 7.4.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Bristol-Myers Squibb Recent Developments
  • 7.5 Italfarmaco
    • 7.5.1 Italfarmaco Profile
    • 7.5.2 Italfarmaco Main Business
    • 7.5.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
    • 7.5.4 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Italfarmaco Recent Developments
  • 7.6 Santhera Pharmaceuticals
    • 7.6.1 Santhera Pharmaceuticals Profile
    • 7.6.2 Santhera Pharmaceuticals Main Business
    • 7.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
    • 7.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Santhera Pharmaceuticals Recent Developments

8 Industry Chain Analysis

  • 8.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industrial Chain
  • 8.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제